Table 1 Association between the PD-L1 expression and patient clinicopathological variables.
Variables | Total (N = 280) | PD-L1 expression | |||
|---|---|---|---|---|---|
< 1% (N = 78) | 1–49% (N = 146) | ≥ 50% (N = 56) | P | ||
Age: ≥ 70 years—no. (%) | 156 (55.7) | 39 (50.0) | 88 (60.3) | 29 (51.8) | 0.27 |
Sex: male—no. (%) | 157 (56.1) | 30 (38.5) | 84 (57.5) | 43 (76.8) | < 0.001 |
Current or former smoker—no. (%) | 174 (62.1) | 40 (51.3) | 87 (59.6) | 47 (83.9) | < 0.001 |
Histological type—no. (%) | < 0.001 | ||||
ADC | 216 (77.1) | 76 (97.4) | 115 (78.7) | 25 (44.6) | |
SCC | 46 (16.4) | 1 (1.3) | 22 (15.1) | 23 (41.1) | |
Othera | 18 (6.4) | 1 (1.3) | 9 (6.2) | 8 (14.3) | |
Pathological stage—no. (%) | < 0.001 | ||||
I | 202 (72.1) | 63 (80.8) | 109 (74.7) | 30 (53.6) | |
II | 50 (17.8) | 12 (15.4) | 23 (15.8) | 15 (26.8) | |
IIIA | 28 (10.0) | 3 (3.8) | 14 (9.6) | 11 (19.6) | |
Surgical procedure—no. (%) | 0.74 | ||||
Lobectomy | 262 (93.6) | 76 (97.4) | 135 (92.5) | 51 (91.1) | |
Bilobectomy | 6 (2.1) | 1 (1.3) | 3 (2.1) | 2 (3.6) | |
Lobectomy with combined resection | 12 (4.3) | 1 (1.3) | 8 (5.5) | 3 (5.4) | |
Lymph node dissection—no. (%) | < 0.001 | ||||
ND1 | 25 (8.9) | 17 (21.8) | 7 (4.8) | 1 (1.8) | |
ND2 | 255 (91.1) | 61 (78.2) | 139 (95.2) | 55 (98.2) | |
Adjuvant therapy—no. (%) | 0.018 | ||||
Platinum-based chemotherapy | 28 (10.0) | 4 (5.1) | 13 (8.9) | 11 (19.6) | |
EGFR mutation—no. (%) | < 0.001 | ||||
Wild-type | 181 (64.6) | 38 (48.7) | 92 (63.0) | 51 (91.1) | |
Ex21 | 48 (17.1) | 19 (24.4) | 28 (19.2) | 1 (1.8) | |
Ex19 | 31 (11.1) | 15 (19.2) | 14 (9.6) | 2 (3.6) | |
Minor mutationb | 20 (7.1) | 6 (7.7) | 12 (8.2) | 2 (3.6) | |
